Pluriomics Stem Cell technology

Cardiac Safety Assays

Pluriomics is using its Pluricyte® Cardiomyocytes and its services on the development of cell-based cardiac safety assays for the prediction of cardiotoxic side effects in early drug development stages.

Human iPSC-derived cardiomyocytes as a highly predictive model for cardiotoxicity

Prevention of drug-induced cardiotoxicity, which manifests itself as cardiac arrhythmias, is the highest priority for regulatory agencies and biopharmaceutical companies, since manifestation of this type of toxicity is immediately life-threatening. 33% of adverse safety events in clinical studies are generally attributed to cardiac arrhythmic effects, which may lead to severe cardiac complications or even sudden death.

Current pre-clinical screening models do not sufficiently predict cardiotoxicity and require improvement. Pluriomics aims to overcome these limitations by providing fully functional human iPSC-derived cardiomyocytes and by offering services on the accompanied biochemical-, contraction- and electrophysiology-based assays, which enhances the prediction of cardiotoxicity of (your) pharmaceutical compounds. 

 Pluriomics focusses on two aspects of safety pharmacology:

  • High-throughput-based early detection of cardiac adverse effects

  • Regulatory safety pharmacology in line with the anticipated Comprehensive In Vitro Proarrhythmia Assay (CiPA) guidelines
    Please, find our CiPA flyer, describing Pluricyte® Cardiomyocyte-based MEA assays for in vitro pro-arrhythmia assays, below:

CiPA front page


Currently, Pluriomics has the following relevant systems available for electrophysiology- and contraction-based assays and can provide in-house services on:

  • xCELLigence® RTCA CardioECR system (ACEA Biosciences)

  • The Maestro system (Axion BioSystems)

  • FLIPR Tetra® High-Throughput Cellular Screening System  (Molecular Devices)


Detailed information on the application of Pluricyte® Cardiomyocytes in several safety pharmacology assays can also be found in our Safety Pharmacology Brochure.

 If you are interested in further information about our services on cardiac safety assays, please contact us via